Education
About Us
Working with TipRanks
Follow Us
Spago Nanomedical AB (DE:7UX)
FRANKFURT:7UX
7UX Stock Chart & Stats
€0.01
>-€0.01(-11.76%)
At close: 4:00 PM EST
€0.01
>-€0.01(-11.76%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.19M
Enterprise Value€13.17M
Total Cash (Recent Filing)€29.67M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.75
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding661,572,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.42
Price to Sales (P/S)99.92
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€93.78K
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt balance sheet materially reduces financial risk and interest obligations for a clinical-stage biotech. Over the next 2–6 months this provides flexibility to prioritize R&D and structure partnerships or financings on better terms, cushioning near-term solvency risks.
Focused Pipeline StrategyA concentrated pipeline (SpagoPix imaging agent and Tumorad theranostic) reflects strategic focus on complementary diagnostic/therapeutic nanomedicine niches. This alignment improves chances for targeted partnerships, regulatory clarity, and clearer clinical development milestones over the medium term.
Improving Net LossesMeaningful narrowing of net losses over multiple years indicates cost discipline or operational progress, which improves runway dynamics and investor confidence. Sustained improvement suggests management can lower cash burn while advancing programs, aiding longer-term sustainability if trend continues.
Bears Say
Persistent Operating Cash BurnConsistently negative operating cash flow shows the company requires external funding to continue operations. Over 2–6 months this structural cash burn limits autonomy, raises dilution risk from financings, and constrains ability to fund clinical activities without partner deals or new capital.
Sharp Revenue ContractionA large, volatile revenue drop highlights weak or non-recurring commercial inflows and limited internal funding capacity. For a pre-commercial biotech, this undermines operational resilience and may slow program advancement or hamper partner negotiations absent stabilizing revenues or committed funding.
Erosion Of Equity And Negative ROESustained losses have materially eroded shareholder equity and produced deeply negative ROE, signaling diminished capital buffers. Over months this weakens financial flexibility for trials, increases dependency on external capital, and could constrain strategic options versus better-capitalized peers.
7UX FAQ
What was Spago Nanomedical AB’s price range in the past 12 months?
Spago Nanomedical AB lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Spago Nanomedical AB’s market cap?
Spago Nanomedical AB’s market cap is €7.19M.
When is Spago Nanomedical AB’s upcoming earnings report date?
Spago Nanomedical AB’s upcoming earnings report date is May 07, 2026 which is in 58 days.
How were Spago Nanomedical AB’s earnings last quarter?
Currently, no data Available
Is Spago Nanomedical AB overvalued?
According to Wall Street analysts Spago Nanomedical AB’s price is currently Overvalued.
Does Spago Nanomedical AB pay dividends?
Spago Nanomedical AB does not currently pay dividends.
What is Spago Nanomedical AB’s EPS estimate?
Spago Nanomedical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Spago Nanomedical AB have?
Spago Nanomedical AB has 661,572,800 shares outstanding.
What happened to Spago Nanomedical AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Spago Nanomedical AB?
Currently, no hedge funds are holding shares in DE:7UX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Spago Nanomedical AB
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
Technical Analysis
Biosergen AB
―
Nanologica AB
―
Lipigon Pharmaceuticals AB
―
Modus Therapeutics Holding AB
―
NextCell Pharma AB
―